“OligoGenie” is a new type of human neural stem cells with many positive features.
It is thought to be effective for nursing patients with neurological disorders.

Patent on this cell and its culture method have already approved by30 countriesincluding Japan, USA and EPO(※).
 (※As of February 13, 2020)

In addition to the patent, we are successful in controling the differentiation process of the cell. These methods are one of our core technologies and fundamental technologies as well.

By using that special technologies, we will research and develop cell therapy products and drug candidates to treat patients. We will also keep expanding our new technologies.

What is "OligoGenie"?
"OligoGenie" is new type of human neural stem cells that can differentiate into oligodendrocytes at 99% efficiency in vitro, which is one of the main components of the stem cells making up the brain as well as nerves and astrocytes.
The role of oligodendrocytes is making a myelin sheat, which acts as an inslator, on the axon of a neuron.

We aim to provide new therapies using "OligoGenie" for patients suffering from neurological diseases without treatment, such as Spinal cord injury and Pelizaeus-Merzbacher disease (PMD).

Features and Characteristics
➤ High differentiation potency to Oligodendrocytes (at 99% efficiency in vitro)
➤ Expression of polysialic acid (PSA) that effects on axonal regeneration on the cell surface
➤ Expandable (>1 billion times)
➤ Multipotent (Capable of differentiating to nerves, astrocytes and oligodendrocytes in vivo)
➤ No tumorigenicity
➤ Low manufacturing cost
➤ Tolerant for freeze and thaw

Compare with Conventional Technologies
Higher therapeutic effect than competitor's products
OligoGenie has a great advantage over competitor’s neural stem cells.
Neural stem cells are thought to be effective in treating spinal cord injury patients by differentiating into oligodendrocytes.
Our cells can diffentiate into oligodendrocytes at 99% efficiency in vitro that is more than 5 times higher than competitor's products.

Lower risk of cancer and manufacturing cost than ES or iPS cell-derived products
OligoGenie has a great advantage over ESC- or iPSC-derived neural stem cells as well because it will not make any tumor and its production cost is much lower than them.
Our cell is expandable more than 1 billion times with no tumorigenicity. They are multipotent and tolerant for freeze and thaw.
Provide New Therapies:
Cell Therapy Products / Drug Screening
OligoGenie can be used as cell therapy products or drug screening for patients with neurological disorders using our advanced culture method.

Target Diseases
 Spinal cord injury,Pelizaeus-Merzbacher disease (PMD), Amyotrophic lateral sclerosis, Multiple sclerosis, Alzheimer disease, Age-related macular degeneration, etc...

■ Target 1: Spinal Cord Injury
Spinal Cord Injury is a serious medical condition cased by sports, daily activities or traffic accidents. When myelin sheath is damaged by the above reasons, electrical signal wouldn’t be transmitted because of electric leakage.
This can lead to lifelong disabilities. In Japan, there are over one million people in the chronic phase of traumatic spinal cord injury and half of them have been forced to use a wheelchair or bedridden.
As a cell therapy product for spinal cord injury, when OligoGenie are transplanted in a damaged area, they are thought to be effective for improving their symptoms.
Effect of OligoGenie on:
 - differentiation into oligodendrocyte and making new myelin sheat
 - promoting development and regeneration of neural axons by expressing polysialic acid on its cell-surface
 - cell protection by secreting several growth factors

■ Target 2: Pelizaeus-Merzbacher disease
Pelizaeus-Merzbacher disease is a rare central nervous system disorder and one of congenital cerebral hypomyelination.
It is specified as a intractable disease and there is no effective treatment at this time.

This occurs as a result of genetic abnormalities that affect growth of the myelin sheath in the central nervous system and development of the cerebral white matter.
As a result, it causes several symptoms, such as rapid involuntary movements of the eyes (nystagmus), delyed development, spastic paralysis, cerebellar ataxia and dystonia.These symptoms can usually begin in early infancy.

As a potential new therapy, we are ready to conduct a clinical trial in Pelizaeus-Merzbacher disease using "OligoGenie".